R&D - Research and development at AROS
AROS consistently implement new technologies based on a very active academic staff. As the microarray and genomic area is constantly changing at a rapid pace, it is very important that AROS staff is at the front of the changes and learning new technologies as soon as they are developed. AROS is used by several companies as a beta-testing site for new technologies, both for equipment, new array types, and new software.
AROS is partly owned by Aarhus University Hospital, and due to this
fact there is a tight relation between the research environment at the
hospital laboratories and AROS. The CEO of AROS, Torben Ørntoft,
is a professor at the University Hospital and heads a large research
group (more than 30 people) focusing on the use of microarrays (expression,
SNP, sequencing) in basic biology and in clinical studies of diseases.
The latter based on very large well annotated tissue banks.
The three founders of AROS have a very long track record in scientific
publishing, and have during the last five years published in high impact
journals like Nature, Nature Genetics, Cancer Cell, JNCI, Blood, Cancer
Research, J. Clin. Invetigation, and New England J Medicine.
See AROS Scientific Publications
AROS has a portfolio of intellectual properties in the area of gene
expression, such as signatures for disease course prediction, and more
basic technical patents. Two patents are issued, others are pending.